Previous Columns by Dr. Pei Lin Chan
Pei Lin Chan, MBBS （IMU), MRCP (UK)
Sarawak General Hospital
Click here to read Dr. Chan’s bio.
Due to recent FDA guidelines, there have been many clinical trials that have demonstrated the cardiovascular safety of various antihyperglycemic medications. In this month’s column, Dr. Chan takes a closer look at sodium glucose transporter-2 (SGLT-2) inhibitors, outlining not only their antihyperglycemic effects but also the associated cardiovascular and renal benefits. Please take a moment to read her column and check back here for her continuing editorial contributions.
September – October 2020
Managing type 2 diabetes during pregnancy can be especially challenging, both for the mother and the health care provider. In this month’s column, Dr. Pei Lin Chan discusses the role of metformin in pregnant women with type 2 diabetes as well as gestational diabetes. Please take a moment to read her column and check back here monthly for her continuing editorial contributions.
In this month’s column, Dr. Pei Lin Chan explores how testosterone has a role in the pathophysiology of diabetes. She discusses the results of various clinical trials that examine the bidirectional relationship between low testosterone and the development of diabetes. Please take a moment to read her column and check back here monthly for her continuing editorial contributions.
As COVID-19 continues to challenge the global community, large health care conferences have shifted from live conferences to virtual programming. Dr. Pei Lin Chan focuses this month’s column on news from the American Diabetes Association’s recent virtual Scientific Sessions. She touches on impactful news from this four-day event that relate to latest advances in the treatment of diabetes.
As the COVID-19 pandemic continues to affect a staggering number of people around the world, new evidence is emerging regarding the implications of those with diabetes and uncontrolled glycemic levels in the inpatient setting. Dr. Pei Lin Chan focuses this month’s column on best practices for managing hyperglycemia that will yield optimal patient outcomes for hospitalized patients.
During this unsettling time of the COVID-19 pandemic, it is important for health care professionals to understand the heightened risks that the virus poses to patients with diabetes. In this month’s column, Dr. Pei Lin Chan focuses on how to best manage diabetes based on the information that is known to date. Given the ever-changing landscape of the virus, please note that her column is updated per it’s posting on April 27, 2020.
Technological advances in glucose monitoring devices have come a long way in assisting patients with diabetes in monitoring their blood sugar levels. In this month’s column, Dr. Pei Lin Chan discusses how these devices can benefit both patients and health care providers in managing both type 1 and type 2 diabetes.
In her latest column, Dr. Pei Lin Chan focuses on whether diabetes remission is possible in obese patients. She references several studies that support the feasibility of remission, when patients follow dietary control measures as well as lifestyle modification.
JANUARY – FEBRUARY 2020
This month, Dr. Pei Lin Chan’s column focuses on the increasing prevalence of type 2 diabetes in young people. She discusses how diabetes differs in this patient segment and sheds light on management options supported by recent clinical studies and new treatment strategies.
This month, Dr. Pei Lin Chan takes an interesting look at metformin, the most widely prescribed oral antidiabetic medication for the treatment of type 2 diabetes since 1957. She explains how recent clinical studies reveal important results with this standard treatment, thus underscoring its consideration for use amidst the current, newer treatment options.
This month, Dr. Pei Lin Chan reports on the European Society of Cardiology’s new guidelines on diabetes, pre-diabetes, and cardiovascular diseases that have been developed in collaboration with the European Association for the Study of Diabetes.
In this month’s column, Dr. Pei Lin Chan takes a close look at a recent study that sheds light on the prevention of type 1 diabetes, the first to show that immune modulation with teplizumab can delay its clinical onset.
Non-Alcoholic Fatty Liver Disease (NAFLD) is a frequently overlooked complication in patients with diabetes and encompasses other potentially progressive diseases including non-alcoholic steatohepatitis (NASH). Take a moment to read Dr. Pei Lin Chan’s column.
With recent clinical trials on new anti-diabetic drugs providing insight into the cardioprotective benefits of these agents, our 2019 Fellow Scholarship winner, Dr. Pei Lin Chan, explores the diabetes and heart failure link.
News from ADA 79th Scientific Sessions
Our 2019 Fellow Scholarship winner, Dr. Pei Lin Chan, recently attended the American Diabetes Association’s 79th Scientific Sessions in San Francisco, California. She has summarized the key sessions in the following article.